Pancras C.W. Hogendoorn

List of Publications by Year
in descending order

386 papers	31,524 citations	2975 93 h-index	6300 158 g-index
393 all docs	393 docs citations	393 times ranked	24717 citing authors

#	Article	IF	Citations
1	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, The, 2004, 364, 1127-1134.	13.7	1,561
2	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 415-423.	10.7	864
3	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Journal of Pathology, 2011, 224, 334-343.	4.5	834
4	Consensus meeting for the management of gastrointestinal stromal tumorsâ€¨ Report of the GIST Consensus Conference of 20â€“21 March 2004, under the auspices of ESMO. Annals of Oncology, 2005, 16, 566-578.	1.2	628
5	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. Cancer Research, 2009, 69, 5383-5391.	0.9	610
6	The Clinical Approach Towards Chondrosarcoma. Oncologist, 2008, 13, 320-329.	3.7	602
7	Sarcoma Derived from Cultured Mesenchymal Stem Cells. Stem Cells, 2007, 25, 371-379.	3.2	601
8	Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncology, The, 2012, 13, 1045-1054.	10.7	432
9	Imatinib mesylate (STI-571 GlivecÂ®, Gleevecâ„¢) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. European Journal of Cancer, 2003, 39, 2006-2011.	2.8	393
10	Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. European Journal of Cancer, 2011, 47, 2431-2445.	2.8	386
11	Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents. Clinical Cancer Research, 2011, 17, 2110-2119.	7.0	365
12	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1396-1408.	10.7	356
13	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
14	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of Clinical Oncology, 2015, 33, 2279-2287.	1.6	329
15	Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup. Journal of the National Cancer Institute, 2007, 99, 112-128.	6.3	314
16	Identification of a novel, recurrent HEY1â€NCOA2 fusion in mesenchymal chondrosarcoma based on a genomeâ€wide screen of exonâ€level expression data. Genes Chromosomes and Cancer, 2012, 51, 127-139.	2.8	276
17	Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancerâ€“Italian Sarcoma Groupâ€“Australasian Gastrointestinal Trials Group Study. Journal of Clinical Oncology, 2005, 23, 5795-5804.	1.6	266
18	Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. European Journal of Cancer, 2005, 41, 2868-2872.	2.8	266

#	Article	IF	Citations
19	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v204-v213.	1.2	264
20	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Journal of Clinical Oncology, 2007, 25, 3144-3150.	1.6	238
21	Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nature Reviews Cancer, 2010, 10, 481-488.	28.4	236
22	Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. Journal of Pathology, 2009, 219, 294-305.	4.5	234
23	EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Annals of Oncology, 2015, 26, 407-414.	1.2	230
24	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. European Journal of Cancer, 2010, 46, 72-83.	2.8	224
25	Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors. American Journal of Surgical Pathology, 2009, 33, 50-57.	3.7	216
26	Cartilaginous Tumors: Fast Contrast-enhanced MR Imaging. Radiology, 2000, 214, 539-546.	7.3	210
27	Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. European Journal of Cancer, 2008, 44, 2433-2436.	2.8	208
28	EWSR1-CREB1 and EWSR1-ATF1 Fusion Genes in Angiomatoid Fibrous Histiocytoma. Clinical Cancer Research, 2007, 13, 7322-7328.	7.0	207
29	Myxoid tumours of soft tissue. Histopathology, 1999, 35, 291-312.	2.9	204
30	The Clinical Approach Toward Giant Cell Tumor of Bone. Oncologist, 2014, 19, 550-561.	3.7	199
31	The histopathological differential diagnosis of gastrointestinal stromal tumours. Journal of Clinical Pathology, 2001, 54, 96-102.	2.0	195
32	Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumineâ€“enhanced MR Imaging in Prediction of Malignancy. Radiology, 2004, 233, 493-502.	7.3	191
33	Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia. Cancer Research, 2005, 65, 11520-11528.	0.9	187
34	The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology. Clinical Cancer Research, 2009, 15, 2259-2268.	7.0	180
35	Impact of EWS-ETS Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial. Journal of Clinical Oncology, 2010, 28, 1982-1988.	1.6	180
36	Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Research Notes, 2011, 4, 1.	1.4	177

#	Article	IF	Citations
37	EXT-Mutation Analysis and Loss of Heterozygosity in Sporadic and Hereditary Osteochondromas and Secondary Chondrosarcomas. American Journal of Human Genetics, 1999, 65, 689-698.	6.2	174
38	Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functionalâ€based study. Journal of Pathology, 2011, 223, 327-335.	4.5	174
39	Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization?. Radiology, 1998, 208, 821-828.	7.3	173
40	Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma.. American Journal of Roentgenology, 1997, 169, 1097-1104.	2.2	172
41	Diffusion-weighted MRI in the characterization of soft-tissue tumors. Journal of Magnetic Resonance Imaging, 2002, 15, 302-307.	3.4	171
42	Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncology, The, 2005, 6, 599-607.	10.7	171
43	Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 Patients. Oncologist, 2011, 16, 1771-1779.	3.7	169
44	Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Annals of Oncology, 2012, 23, 1607-1616.	1.2	166
45	Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.. American Journal of Roentgenology, 1995, 165, 593-598.	2.2	165
46	Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics, 2013, 45, 1428-1430.	21.4	164
47	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Modern Pathology, 2016, 29, 582-590.	5.5	164
48	First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study. Annals of Oncology, 2011, 22, 207-214.	1.2	163
49	Technical Considerations in CT-Guided Radiofrequency Thermal Ablation of Osteoid Osteoma: Tricks of the Trade. American Journal of Roentgenology, 2002, 179, 1633-1642.	2.2	162
50	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology, 2010, 57, 259-270.	2.9	162
51	Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings.. Radiology, 1993, 186, 813-817.	7.3	159
52	A phase 2 trial of R1507, a monoclonal antibody to the insulinâ€like growth factorâ€1 receptor (IGFâ€1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer, 2014, 120, 2448-2456.	4.1	158
53	Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. European Journal of Cancer, 2002, 38, 1218-1225.	2.8	157
54	Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Laboratory Investigation, 2011, 91, 1195-1205.	3.7	155

#	Article	IF	Citations
55	A nationâ€wide study comparing sporadic and familial adenomatous polyposisâ€related desmoidâ€type fibromatoses. International Journal of Cancer, 2011, 129, 256-261.	5.1	154
56	Aberrant Chemokine Receptor Expression and Chemokine Production by Langerhans Cells Underlies the Pathogenesis of Langerhans Cell Histiocytosis. Journal of Experimental Medicine, 2003, 197, 1385-1390.	8.5	152
57	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. Journal of Clinical Oncology, 2017, 35, 1713-1720.	1.6	148
58	Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene, 2004, 23, 4076-4083.	5.9	146
59	Molecular characterization of commonly used cell lines for bone tumor research: A transâ€European EuroBoNet effort. Genes Chromosomes and Cancer, 2010, 49, 40-51.	2.8	141
60	Inactive Wnt/Î²â€catenin pathway in conventional highâ€grade osteosarcoma. Journal of Pathology, 2010, 220, 24-33.	4.5	138
61	Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: Basic principles and clinical applications. Journal of Magnetic Resonance Imaging, 1996, 6, 311-321.	3.4	137
62	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Annals of Oncology, 2014, 25, 2425-2432.	1.2	135
63	Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiology, 1998, 27, 57-71.	2.0	132
64	Primary non-Hodgkinâ€™s lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia, 1999, 13, 2094-2098.	7.2	131
65	Langerhans-cell histiocytosis 'insight into DC biology'. Trends in Immunology, 2003, 24, 190-196.	6.8	131
66	Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma. Laboratory Investigation, 2000, 80, 1925-1934.	3.7	130
67	Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Modern Pathology, 2006, 19, 407-416.	5.5	130
68	Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). British Journal of Cancer, 2001, 84, 535-538.	6.4	126
69	Proâ€inflammatory chemokineâ€“chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8⁺ Tâ€lymphocyte infiltration and affect tumour progression. Journal of Pathology, 2011, 223, 347-357.	4.5	124
70	Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer, 2010, 10, 462.	2.6	119
71	Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis and Rheumatism, 2007, 56, 586-595.	6.7	118
72	Sclerostin in Mineralized Matrices and van Buchem Disease. Journal of Dental Research, 2009, 88, 569-574.	5.2	117

#	Article	IF	Citations
73	Imaging mass spectrometry statistical analysis. Journal of Proteomics, 2012, 75, 4962-4989.	2.4	117
74	Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. European Journal of Cancer, 2011, 47, 895-902.	2.8	116
75	De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. Journal of Pathology, 2015, 235, 3-13.	4.5	116
76	Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosisâ€"an EORTC STBSG and ROG study (EORTC 62991â€"22998). Annals of Oncology, 2013, 24, 2672-2676.	1.2	115
77	Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer, 2002, 38, 556-559.	2.8	113
78	Cathepsin K Is the Principal Protease in Giant Cell Tumor of Bone. American Journal of Pathology, 2004, 165, 593-600.	3.8	113
79	Noraâ€™s lesion, a distinct radiological entity?. Skeletal Radiology, 2006, 35, 497-502.	2.0	111
80	Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Modern Pathology, 2012, 25, 1378-1383.	5.5	111
81	Transactivating mutation of theMYOD1gene is a frequent event in adult spindle cell rhabdomyosarcoma. Journal of Pathology, 2014, 232, 300-307.	4.5	111
82	NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Molecular Immunology, 2008, 45, 3917-3925.	2.2	108
83	Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes and Cancer, 2012, 51, 696-706.	2.8	108
84	Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. Journal of Experimental Medicine, 2005, 201, 687-693.	8.5	107
85	Genomeâ€wide transcriptome analyses reveal p53 inactivation mediated loss of miRâ€34a expression in malignant peripheral nerve sheath tumours. Journal of Pathology, 2010, 220, 58-70.	4.5	106
86	Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. British Journal of Cancer, 2008, 98, 434-442.	6.4	104
87	Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment. Cancer Research, 2009, 69, 6216-6222.	0.9	102
88	Langerhans cell histiocytosis: fascinating dynamics of the dendritic cellâ€"macrophage lineage. Immunological Reviews, 2010, 234, 213-232.	6.0	102
89	The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. Journal of Pathology, 2011, 223, 336-346.	4.5	102
90	The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions. Journal of the National Cancer Institute, 2007, 99, 396-406.	6.3	101

#	Article	IF	Citations
91	Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas. Journal of Thoracic Oncology, 2009, 4, 1270-1273.	1.1	101
92	Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad. Stem Cells, 2011, 29, 397-403.	3.2	98
93	Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. Clinical Cancer Research, 2012, 18, 432-441.	7.0	97
94	Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. Journal of Pathology, 2010, 222, 400-409.	4.5	96
95	Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial. Journal of Clinical Oncology, 2009, 27, 3969-3974.	1.6	95
96	Lymphatics and bone. Human Pathology, 2008, 39, 49-55.	2.0	94
97	ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Critical Reviews in Oncology/Hematology, 2017, 110, 94-105.	4.4	94
98	MR imaging of clear cell sarcoma (malignant melanoma of the soft parts): a multicenter correlative MRI-pathology study of 21 cases and literature review. Skeletal Radiology, 2000, 29, 187-195.	2.0	93
99	Molecular pathology of sarcomas: concepts and clinical implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 193-199.	2.8	93
100	Antiâ€inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitorâ€treated gastrointestinal stromal tumors. International Journal of Cancer, 2010, 127, 899-909.	5.1	92
101	Chondroma and chondrosarcoma of the larynx. Current Opinion in Otolaryngology and Head and Neck Surgery, 2004, 12, 98-105.	1.8	91
102	1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene, 2012, 31, 1287-1298.	5.9	91
103	Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget, 2015, 6, 38777-38788.	1.8	90
104	Multiple Statistical Analysis Techniques Corroborate Intratumor Heterogeneity in Imaging Mass Spectrometry Datasets of Myxofibrosarcoma. PLoS ONE, 2011, 6, e24913.	2.5	89
105	MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet Journal of Rare Diseases, 2013, 8, 7.	2.7	89
106	Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. European Journal of Human Genetics, 2003, 11, 611-618.	2.8	87
107	Reduced human leukocyte antigen expression in advancedâ€stage Ewing sarcoma: implications for immune recognition. Journal of Pathology, 2009, 218, 222-231.	4.5	87
108	Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. PLoS ONE, 2012, 7, e48262.	2.5	87

#	Article	IF	Citations
109	Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. Journal of Pathology, 2005, 205, 476-482.	4.5	86
110	Desmoplastic fibroma of bone: an immunohistochemical study including -catenin expression and mutational analysis for -catenin. Human Pathology, 2005, 36, 1025-1030.	2.0	85
111	Pathology of primary malignant bone and cartilage tumours. International Orthopaedics, 2006, 30, 437-444.	1.9	85
112	SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology. Journal of Pathology, 2003, 201, 480-486.	4.5	83
113	Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 downâ€regulation and p16 overexpression inhibit cell growth in vitro. Journal of Cellular and Molecular Medicine, 2009, 13, 2843-2852.	3.6	83
114	Telomereâ€associated proteins: crossâ€talk between telomere maintenance and telomereâ€lengthening mechanisms. Journal of Pathology, 2009, 217, 327-344.	4.5	82
115	Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study. Journal of Clinical Oncology, 1999, 17, 3260-3269.	1.6	80
116	Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional(central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. Journal of Pathology, 2004, 202, 359-366.	4.5	80
117	Coactivated Platelet-Derived Growth Factor Receptor Î± and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. Cancer Research, 2010, 70, 7304-7314.	0.9	80
118	Molecular pathology and its diagnostic use in bone tumors. Cancer Genetics, 2012, 205, 193-204.	0.4	80
119	Diagnosis and prognosis of chondrosarcoma of bone. Expert Review of Molecular Diagnostics, 2002, 2, 461-472.	3.1	79
120	Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. Gynecologic Oncology, 2009, 112, 572-576.	1.4	78
121	Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 561-570.	2.8	78
122	Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunology, Immunotherapy, 2011, 60, 575-586.	4.2	76
123	Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Human Pathology, 1996, 27, 904-911.	2.0	75
124	Aggressive angiomyxoma: a clinicopathological and immunohistochemical study of 11 cases with long-term follow-up. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 157-163.	2.8	75
125	GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. Nature Genetics, 2014, 46, 474-477.	21.4	75
126	Adamantinoma of the Long Bones: Keratin Subclass Immunoreactivity Pattern with Reference to Its Histogenesis. American Journal of Surgical Pathology, 1993, 17, 1225-1233.	3.7	73

#	Article	IF	Citations
127	Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3. Cancer Research, 2004, 64, 3395-3405.	0.9	73
128	Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Laboratory Investigation, 2010, 90, 1091-1101.	3.7	73
129	IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer, 2013, 13, 245.	2.6	73
130	Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors. Clinical Cancer Research, 2009, 15, 2685-2694.	7.0	71
131	No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes and Cancer, 2009, 48, 239-249.	2.8	71
132	Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: a comparison of various antigen retrieval systems using microwave heating and proteolytic pre-treatments.. Journal of Histochemistry and Cytochemistry, 1995, 43, 429-437.	2.5	70
133	Amplification of 17p11.2â^¼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genetics and Cytogenetics, 2002, 139, 91-96.	1.0	70
134	Incidence of Biopsy-Proven Bone Tumors in Children. Journal of Pediatric Orthopaedics, 2008, 28, 29-35.	1.2	70
135	Prognostic factors in pulmonary metastasized highâ€grade osteosarcoma. Pediatric Blood and Cancer, 2010, 54, 216-221.	1.5	69
136	The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). Journal of Bone and Joint Surgery: British Volume, 2012, 94-B, 882-888.	3.4	69
137	Expression of Cell Cycleâ€“Related Gene Products in Langerhans Cell Histiocytosis. Journal of Pediatric Hematology/Oncology, 2002, 24, 727-732.	0.6	68
138	Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Human Mutation, 2004, 24, 466-473.	2.5	68
139	Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene, 2011, 30, 334-345.	5.9	68
140	Cytogenetic analysis of adamantinoma of long bones: Further indications for a common histogenesis with osteofibrous dysplasia. Cancer Genetics and Cytogenetics, 1997, 97, 5-11.	1.0	67
141	Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. European Journal of Cancer, 2004, 40, 963-970.	2.8	67
142	Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. British Journal of Cancer, 2009, 101, 1909-1918.	6.4	67
143	No Haploinsufficiency but Loss of Heterozygosity for EXT in Multiple Osteochondromas. American Journal of Pathology, 2010, 177, 1946-1957.	3.8	67
144	Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. Journal of Pathology, 2006, 209, 501-511.	4.5	66

#	Article	IF	Citations
145	Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene, 2012, 31, 1095-1104.	5.9	66
146	Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. Journal of Cellular and Molecular Medicine, 2009, 13, 1291-1301.	3.6	65
147	Tumor-Associated Macrophages Are Related to Volumetric Growth of Vestibular Schwannomas. Otology and Neurotology, 2013, 34, 347-352.	1.3	65
148	Low-Grade Chondrosarcoma of Long Bones Treated with Intralesional Curettage Followed by Application of Phenol, Ethanol, and Bone-Grafting. Journal of Bone and Joint Surgery - Series A, 2012, 94, 1201-1207.	3.0	64
149	Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor. International Journal of Cancer, 2013, 133, n/a-n/a.	5.1	64
150	Clear cell sarcoma of the stomach. Histopathology, 2002, 41, 526-530.	2.9	63
151	Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy.. Radiology, 1994, 191, 421-431.	7.3	62
152	Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response.. American Journal of Roentgenology, 1995, 165, 125-133.	2.2	62
153	Retain or sacrifice the posterior cruciate ligament in total knee arthroplasty? A histopathological study of the cruciate ligament in osteoarthritic and rheumatoid disease. Journal of Clinical Pathology, 2001, 54, 381-384.	2.0	61
154	MRI of Adamantinoma of Long Bones in Correlation with Histopathology. American Journal of Roentgenology, 2004, 183, 1737-1744.	2.2	61
155	Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2009, 15, 4191-4198.	7.0	61
156	Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?. Clinical Radiology, 1995, 50, 384-390.	1.1	60
157	A multidisciplinary approach to giant cell tumors of tendon sheath and synoviumâ€"A critical appraisal of literature and treatment proposal. Journal of Surgical Oncology, 2013, 107, 433-445.	1.7	60
158	ALK-positiveÂhistiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood, 2022, 139, 256-280.	1.4	60
159	Near-Haploidy and Subsequent Polyploidization Characterize the Progression of Peripheral Chondrosarcoma. American Journal of Pathology, 2000, 157, 1587-1595.	3.8	59
160	Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. European Radiology, 2003, 13, 1849-1858.	4.5	59
161	Benign Cartilaginous Tumors of Bone. Advances in Anatomic Pathology, 2009, 16, 307-315.	4.3	59
162	Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Medical Genomics, 2014, 7, 4.	1.5	59

#	Article	IF	Citations
163	Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer. Cancer Research, 2012, 72, 4074-4084.	0.9	58
164	Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. Journal of Pathology, 2007, 211, 399-409.	4.5	57
165	Distinct histological features characterize primary angiosarcoma of bone. Histopathology, 2011, 58, 254-264.	2.9	57
166	A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone. American Journal of Surgical Pathology, 2010, 34, 777-783.	3.7	55
167	A short-term in vivo model for giant cell tumor of bone. BMC Cancer, 2011, 11, 241.	2.6	54
168	Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes. International Journal of Molecular Sciences, 2015, 16, 16176-16215.	4.1	54
169	Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study. Human Pathology, 2000, 31, 1299-1303.	2.0	53
170	Magnetic resonance imaging of knee cartilage using a water selective balanced steady-state free precession sequence. Journal of Magnetic Resonance Imaging, 2004, 20, 850-856.	3.4	53
171	A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. European Journal of Cancer, 2004, 40, 1327-1331.	2.8	53
172	Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma. Clinical Cancer Research, 2005, 11, 8028-8035.	7.0	53
173	Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. European Journal of Cancer, 2005, 41, 225-230.	2.8	53
174	Pathogenesis of experimental lupus nephritis: a role foranti-basement membrane and anti-tubular brush border antibodiesin murine chronic graft-versus-hostdisease. Clinical and Experimental Immunology, 2008, 79, 115-122.	2.6	53
175	A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. Oncologist, 2008, 13, 467-473.	3.7	53
176	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFÎ² as Potential Targets. American Journal of Pathology, 2013, 182, 1347-1356.	3.8	53
177	Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes and Cancer, 2010, 49, 1095-1103.	2.8	52
178	Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 629-636.	2.8	52
179	Soft Tissue Tumours of the Retroperitoneum. Sarcoma, 2000, 4, 17-26.	1.3	51
180	Array-comparative genomic hybridization of central chondrosarcoma. Cancer, 2006, 107, 380-388.	4.1	51

#	Article	IF	Citations
181	Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging. Skeletal Radiology, 1994, 23, 493-500.	2.0	50
182	Lymph node staging standards in gastric cancer.. Journal of Clinical Oncology, 1995, 13, 2309-2316.	1.6	50
183	cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade. Journal of Pathology, 2005, 207, 61-71.	4.5	50
184	A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. Journal of Pathology, 2008, 216, 158-166.	4.5	50
185	Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients. Human Mutation, 2011, 32, E2036-E2049.	2.5	50
186	Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens. Biomaterials, 2012, 33, 181-188.	11.4	50
187	Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations. European Journal of Human Genetics, 2005, 13, 470-474.	2.8	49
188	Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma. PLoS ONE, 2009, 4, e7987.	2.5	49
189	Langerhans cell histiocytosis: A pathologic combination of oncogenesis and immune dysregulation. Pediatric Blood and Cancer, 2004, 42, 401-403.	1.5	48
190	MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance. Skeletal Radiology, 2007, 36, 937-944.	2.0	48
191	Synovial sarcoma: dynamic contrast-enhanced MR imaging features. Skeletal Radiology, 2001, 30, 25-30.	2.0	47
192	Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology, 2010, 56, 641-651.	2.9	46
193	Expression of cartilage growth plate signalling molecules in chondroblastoma. Journal of Pathology, 2004, 202, 113-120.	4.5	45
194	Brachyury and chordoma: the chondroidâ€“chordoid dilemma resolved?. Journal of Pathology, 2006, 209, 143-146.	4.5	45
195	Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. European Journal of Cancer, 2007, 43, 308-315.	2.8	45
196	Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and arrayâ€CGH analysis. Genes Chromosomes and Cancer, 2009, 48, 468-479.	2.8	45
197	Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study. European Journal of Surgical Oncology, 2009, 35, 1326-1332.	1.0	45
198	Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. European Journal of Cancer, 2004, 40, 1644-1654.	2.8	44

#	Article	IF	Citations
199	A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. Annals of Oncology, 1999, 10, 1211-1218.	1.2	43
200	The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. European Journal of Cancer, 2012, 48, 3429-3438.	2.8	43
201	Aberrant Heparan Sulfate Proteoglycan Localization, Despite Normal Exostosin, in Central Chondrosarcoma. American Journal of Pathology, 2009, 174, 979-988.	3.8	42
202	Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup. European Journal of Cancer, 2012, 48, 703-712.	2.8	42
203	Ewing sarcoma inhibition by disruption of <scp>EWSR1â€“FLI1</scp> transcriptional activity and reactivation of p53. Journal of Pathology, 2014, 233, 415-424.	4.5	42
204	Myxoid tumours of soft tissue: the soâ€called myxoid extracellular matrix is heterogeneous in composition. Histopathology, 2008, 52, 465-474.	2.9	41
205	IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis. PLoS ONE, 2011, 6, e19846.	2.5	41
206	MR imaging based strategies in limb salvage surgery for osteosarcoma of the distal femur. Skeletal Radiology, 1997, 26, 636-641.	2.0	40
207	Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. Journal of Clinical Pathology, 2009, 62, 820-824.	2.0	40
208	Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. Journal of Lipid Research, 2013, 54, 2195-2205.	4.2	40
209	Chromosome 9 Alterations and Trisomy 22 in Central Chondrosarcoma: A Cytogenetic and DNA Flow Cytometric Analysis of Chondrosarcoma Subtypes. Diagnostic Molecular Pathology, 2001, 10, 228-235.	2.1	40
210	Adamantinoma-like Ewing's sarcoma and Ewing's-like adamantinoma. The t(11; 22), t(21; 22) status. Journal of Pathology, 2001, 195, 218-221.	4.5	39
211	CD33+ CD14â^' Phenotype Is Characteristic of Multinuclear Osteoclast-Like Cells in Giant Cell Tumor of Bone. Journal of Bone and Mineral Research, 2009, 24, 70-77.	2.8	39
212	Running GAGs: myxoid matrix in tumor pathology revisited. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 181-192.	2.8	39
213	The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 221-229.	2.8	39
214	Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. Oncotarget, 2015, 6, 36113-36125.	1.8	39
215	The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 430-437.	2.8	38
216	Clinico-histologic parameters of osteosarcoma patients with late relapse. European Journal of Cancer, 2006, 42, 460-466.	2.8	38

#	Article	IF	Citations
217	Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nuclear Medicine and Biology, 2006, 33, 831-840.	0.6	38
218	Gastrointestinal Stromal Tumors I: Pathology, Pathobiology, Primary Therapy, and Surgical Issues. Seminars in Oncology, 2009, 36, 290-301.	2.2	38
219	Cartilage ultrastructure in proteoglycanâ€deficient zebrafish mutants brings to light new candidate genes for human skeletal disorders. Journal of Pathology, 2011, 223, 531-542.	4.5	38
220	Avenâ€mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. Journal of Pathology, 2015, 236, 348-359.	4.5	38
221	Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. European Journal of Cancer, 2016, 53, 171-180.	2.8	38
222	Giant cell tumors of the tendon sheath may present radiologically as intrinsic osseous lesions. European Radiology, 2007, 17, 499-502.	4.5	37
223	The immunophenotype of osteoclasts and macrophage polykaryons. Journal of Clinical Pathology, 2011, 64, 701-705.	2.0	37
224	Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Modern Pathology, 2012, 25, 1275-1283.	5.5	37
225	Genome-wide analysis of Ollier disease: Is it all in the genes?. Orphanet Journal of Rare Diseases, 2011, 6, 2.	2.7	36
226	Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer, 2012, 12, 375.	2.6	36
227	Tumor Biology of Vestibular Schwannoma. Otology and Neurotology, 2015, 36, 1128-1136.	1.3	36
228	Detection of areas with viable remnant tumor in postchemotherapy patients with Ewingâ€™s sarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling. Magnetic Resonance Imaging, 2000, 18, 525-535.	1.8	35
229	Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype. Modern Pathology, 2004, 17, 1434-1439.	5.5	35
230	Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. Cancer Genetics and Cytogenetics, 2006, 166, 173-179.	1.0	34
231	Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. European Journal of Cancer, 2008, 44, 1855-1860.	2.8	34
232	Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. European Journal of Cancer, 2014, 50, 388-396.	2.8	34
233	Dedifferentiated Adamantinoma With Revertant Mesenchymal Phenotype. American Journal of Surgical Pathology, 2003, 27, 1530-1537.	3.7	33
234	Telomere biology in giant cell tumour of bone. Journal of Pathology, 2008, 214, 555-563.	4.5	33

#	Article	IF	Citations
235	Inactivation of Patched1 in Mice Leads to Development of Gastrointestinal Stromal-Like Tumors That Express Pdgfrî± but Not Kit. Gastroenterology, 2013, 144, 134-144.e6.	1.3	33
236	Does magnetic resonance imaging make a difference for patients with musculoskeletal sarcoma?. British Journal of Radiology, 1997, 70, 327-337.	2.2	32
237	Chondroblastic osteosarcoma: characterisation by gadolinium-enhanced MR imaging correlated with histopathology. Skeletal Radiology, 1998, 27, 145-153.	2.0	32
238	Langerhans-cell histiocytosis: neoplasia or unbridled inflammation?. Trends in Immunology, 2003, 24, 409-410.	6.8	32
239	Solitary fibrous tumour: the emerging clinicopathologic spectrum of an entity and its differential diagnosis. Current Diagnostic Pathology, 2004, 10, 229-235.	0.4	32
240	Heterogeneous and Complex Rearrangements of Chromosome Arm 6q in Chondromyxoid Fibroma. American Journal of Pathology, 2010, 177, 1365-1376.	3.8	32
241	The First European Interdisciplinary Ewing Sarcoma Research Summit. Frontiers in Oncology, 2012, 2, 54.	2.8	32
242	Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma?. Skeletal Radiology, 1996, 25, 19-24.	2.0	31
243	Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. Modern Pathology, 2009, 22, 1489-1498.	5.5	31
244	Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone. Skeletal Radiology, 1994, 23, 501-507.	2.0	30
245	mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Medical Genomics, 2011, 4, 66.	1.5	30
246	High frequency of MYC gene amplification is a common feature of radiationâ€induced sarcomas. Further results from EORTC STBSG TL 01/01. Genes Chromosomes and Cancer, 2013, 52, 93-98.	2.8	30
247	CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients. European Journal of Cancer, 2015, 51, 2624-2633.	2.8	30
248	HSPG-Deficient Zebrafish Uncovers Dental Aspect of Multiple Osteochondromas. PLoS ONE, 2012, 7, e29734.	2.5	30
249	Keratin immunoreactivity in melanoma of soft parts (clear cell sarcoma). Histopathology, 1995, 27, 61-65.	2.9	29
250	Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype. Histopathology, 2015, 67, 483-490.	2.9	29
251	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta OncolÃ³gica, 2017, 56, 1013-1020.	1.8	29
252	Nonâ€ossifying fibroma: A RASâ€MAPK driven benign bone neoplasm. Journal of Pathology, 2019, 248, 127-130.	4.5	29

#	Article	IF	Citations
253	M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 375-381.	2.8	29
254	Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway. PLoS ONE, 2013, 8, e80725.	2.5	29
255	Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways. Clinical Cancer Research, 2007, 13, 206-214.	7.0	28
256	An osteosarcoma zebrafish model implicates Mmpâ€19 and Etsâ€1 as well as reduced host immune response in angiogenesis and migration. Journal of Pathology, 2012, 227, 245-253.	4.5	28
257	MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Genes and Cancer, 2015, 6, 503-512.	1.9	28
258	Chondromyxoid fibroma resemblesin vitro chondrogenesis, but differs in expression of signalling molecules. Journal of Pathology, 2005, 206, 135-142.	4.5	27
259	Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation. Human Pathology, 1997, 28, 183-188.	2.0	26
260	Accuracy of radiography in grading and tissue-specific diagnosisâ€"a study of 200 consecutive bone tumors of the hand. Skeletal Radiology, 2006, 35, 78-87.	2.0	26
261	Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 Multiple Osteochondromas families. BMC Medical Genetics, 2011, 12, 85.	2.1	26
262	Osteosarcoma Models: From Cell Lines to Zebrafish. Sarcoma, 2012, 2012, 1-11.	1.3	26
263	Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. Journal of Pathology, 2012, 226, 219-228.	4.5	26
264	The role of noncartilage-specific molecules in differentiation of cartilaginous tumors. Cancer, 2007, 110, 385-394.	4.1	25
265	Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genetics and Cytogenetics, 2007, 172, 12-22.	1.0	25
266	Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option. Molecular Cancer, 2010, 9, 257.	19.2	25
267	Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation. Journal of Pathology: Clinical Research, 2021, 7, 10-26.	3.0	25
268	TGF-Î²1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. Journal of Pathology, 2006, 208, 26-34.	4.5	24
269	Smooth muscle actin expression in primary bone tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 525-534.	2.8	24
270	Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 109-120.	2.8	24

#	Article	IF	Citations
271	Imaging Mass Spectrometry-based Molecular Histology Differentiates Microscopically Identical and Heterogeneous Tumors. Journal of Proteome Research, 2013, 12, 1847-1855.	3.7	24
272	Hemicortical allograft reconstruction after resection of low-grade malignant bone tumours. Journal of Bone and Joint Surgery: British Volume, 2002, 84, 1009-1014.	3.4	24
273	Late sarcoma development after curettage and bone grafting of benign bone tumors. European Journal of Radiology, 2011, 77, 19-25.	2.6	23
274	Growth plate regulation and osteochondroma formation: insights from tracing proteoglycans in zebrafish models and human cartilage. Journal of Pathology, 2011, 224, 160-168.	4.5	23
275	The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 229-239.	2.8	23
276	Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1793-1803.	6.4	22
277	Results of Diagnostic Review in Pediatric Bone Tumors and Tumorlike Lesions. Journal of Pediatric Orthopaedics, 2008, 28, 561-564.	1.2	22
278	Increased HIF1Î± in SDH and FH deficient tumors does not cause microsatellite instability. International Journal of Cancer, 2007, 121, 1386-1389.	5.1	21
279	Ring Chromosome 4 as the Sole Cytogenetic Anomaly in a Chondroblastoma. Cancer Genetics and Cytogenetics, 1998, 105, 109-112.	1.0	20
280	Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones. Modern Pathology, 2012, 25, 56-64.	5.5	20
281	<scp>CD</scp>99â€positive undifferentiated round cell sarcoma diagnosed on fine needle aspiration cytology, later found to harbour a <scp>CIC</scp>â€<scp>DUX</scp>4 translocation: a recently described entity. Cytopathology, 2014, 25, 129-132.	0.7	20
282	A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. Cancer Chemotherapy and Pharmacology, 2019, 83, 951-962.	2.3	20
283	Development of Progressive Glomerulosclerosis in Experimental Chronic Serum Sickness. Nephrology Dialysis Transplantation, 1990, 5, 100-109.	0.7	19
284	Extraâ€abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. Journal of Cutaneous Pathology, 2009, 36, 565-569.	1.3	19
285	Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma. Journal of Cellular Physiology, 2010, 225, 601-611.	4.1	19
286	Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 41-46.	2.8	19
287	A balanced t(5;17) (p15;q22-23) in chondroblastoma: frequency of the re-arrangement and analysis of the candidate genes. BMC Cancer, 2009, 9, 393.	2.6	18
288	A Î”Raf1â€“ERâ€inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. Journal of Pathology, 2011, 225, 19-28.	4.5	18

#	Article	IF	Citations
289	Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients. Cancer Immunology, Immunotherapy, 2012, 61, 941-947.	4.2	18
290	Infantileâ€type digital fibromatosis tumour in an adult. British Journal of Dermatology, 2000, 143, 1107-1108.	1.5	17
291	Multicolor fluorescence in situ hybridization analysis of a synovial sarcoma of the larynx with a t(X;18)(p11.2;q11.2) and trisomies 2 and 8. Cancer Genetics and Cytogenetics, 2004, 153, 48-52.	1.0	17
292	Unusual Manifestations of Yersinia enterocolitica Infections Diagnosed Using Novel Methods. Clinical Infectious Diseases, 1992, 15, 645-649.	5.8	16
293	Cartilage-forming tumours of bone and soft tissue and their differential diagnosis. Current Diagnostic Pathology, 2001, 7, 223-234.	0.4	16
294	Limited Rescue of Osteoclast-Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor. Journal of Bone and Mineral Research, 2005, 20, 2264-2270.	2.8	16
295	Chondroid lipoma: findings on radiography and MRI (2006:7b). European Radiology, 2006, 16, 2373-2376.	4.5	16
296	Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. Journal of Clinical Pathology, 2010, 63, 1095-1100.	2.0	16
297	Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 95-102.	2.8	16
298	Prognosis of Primary and Recurrent Chondrosarcoma of the Rib. Annals of Surgical Oncology, 2016, 23, 811-817.	1.5	16
299	Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. Oncologist, 2019, 24, 889-e421.	3.7	16
300	Absence of Epstein-Barr virus (EBV) in a gastrointestinal stromal cell tumour (GIST) in an adult human immunodeficiency virus-seropositive patient with past EBV infection. European Journal of Gastroenterology and Hepatology, 1997, 9, 721-724.	1.6	15
301	Bifurcation of the femur with tibial agenesis and additional anomalies. American Journal of Medical Genetics, Part A, 2005, 138A, 45-50.	1.2	15
302	Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis. PLoS ONE, 2014, 9, e107105.	2.5	15
303	Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 703-713.	2.8	15
304	Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 995-1002.	4.2	15
305	Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 135-146.	2.8	15
306	Translocation Identification of an Ews-Pseudogene Using Detection by RT-PCR in Ewings-Sarcoma. Biochemical and Biophysical Research Communications, 1995, 213, 1051-1060.	2.1	14

#	Article	IF	Citations
307	Prenatal Detection of Orbital Rhabdomyosarcoma. JAMA Ophthalmology, 2005, 123, 276.	2.4	14
308	Corrections to â€œConsensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20â€“21 March 2004, under the auspices of ESMOâ€• Annals of Oncology, 2005, 16, 993.	1.2	14
309	Basic fibroblast growth factor and fibroblastic growth factor receptorâ€“1 may contribute to head and neck paraganglioma development by an autocrine or paracrine mechanism. Human Pathology, 2007, 38, 79-85.	2.0	14
310	Neoadjuvant denosumab for extensive giant cell tumor in os ischium â€”a case report. Monthly Notices of the Royal Astronomical Society: Letters, 2015, 86, 393-395.	3.3	14
311	Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports. European Review for Medical and Pharmacological Sciences, 2021, 25, 1670-1679.	0.7	14
312	Endothelial Activation Antigens in Pulmonary Leukostasis in Leukemia. Acta Haematologica, 1993, 90, 29-33.	1.4	13
313	An association between cartilaginous tumours and breast cancer in the national pathology registration in The Netherlands points towards a possible genetic trait. Journal of Pathology, 2001, 193, 190-192.	4.5	13
314	Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis. Cancers, 2021, 13, 5119.	3.7	13
315	The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27. Journal of Bone and Joint Surgery: British Volume, 2008, 90-B, 1528-1532.	3.4	12
316	Paratesticular desmoplastic small round cell tumour: an unusual tumour with an unusual fusion; cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH. Clinical Sarcoma Research, 2012, 2, 3.	2.3	12
317	Possible effects of EXT2 on mesenchymal differentiation - lessons from the zebrafish. Orphanet Journal of Rare Diseases, 2014, 9, 35.	2.7	12
318	Nikolay Ivanovich Pirogov (1810â€“1881): A pioneering Russian surgeon and medical scientist. Journal of Medical Biography, 2018, 26, 10-22.	0.1	12
319	Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma. Journal of Surgical Oncology, 2018, 118, 906-914.	1.7	12
320	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1703-1713.	3.0	12
321	Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases. Annals of Diagnostic Pathology, 2022, 57, 151882.	1.3	12
322	Scale-invariant segmentation of dynamic contrast-enhanced perfusion MR images with inherent scale selection. Computer Animation and Virtual Worlds, 2002, 13, 1-19.	0.9	11
323	A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. Laboratory Investigation, 2004, 84, 191-202.	3.7	11
324	Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations. Current Diagnostic Pathology, 2005, 11, 390-399.	0.4	11

#	Article	IF	Citations
325	Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis. BMC Medical Genomics, 2009, 2, 25.	1.5	11
326	â€˜The chicken or the egg?â€™ dilemma strikes back for the controlling mechanism in chordoma[#]. Journal of Pathology, 2012, 228, 261-265.	4.5	11
327	Nikolay Ivanovich Pirogov: a surgeon's contribution to military and civilian anaesthesia. Anaesthesia, 2015, 70, 219-227.	3.8	11
328	Increased dynamin expression precedes proteinuria in glomerular disease. Journal of Pathology, 2019, 247, 177-185.	4.5	11
329	Nikolay Ivanovich Pirogov (1810â€“1881): Anatomical research to develop surgery. Clinical Anatomy, 2020, 33, 714-730.	2.7	11
330	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Advances, 2021, 5, 3760-3775.	5.2	11
331	Metastasis of Breast Carcinoma to a Primary Mucinous Cystadenocarcinoma of the Ovary. Gynecologic Oncology, 1994, 52, 80-86.	1.4	10
332	How is the mutational status for tumor suppressors p53 and p16INK4A in MFH of the bone?. Cancer Letters, 1998, 123, 147-151.	7.2	10
333	Bone tumors. European Radiology, 2000, 10, 207-212.	4.5	10
334	Novel splice variants of CXCR4 identified by transcriptome sequencing. Biochemical and Biophysical Research Communications, 2015, 466, 89-94.	2.1	10
335	Glomerular permeability is not affected by heparan sulfate glycosaminoglycan deficiency in zebrafish embryos. American Journal of Physiology - Renal Physiology, 2019, 317, F1211-F1216.	2.7	10
336	Primary intraosseous manifestation of Rosai-Dorfman disease: 2 cases and review of literature. Journal of the Belgian Society of Radiology, 2015, 97, 84.	0.2	10
337	Molecular Identification of a Partial Hydatidiform Mole. Diagnostic Molecular Pathology, 1997, 6, 58-63.	2.1	9
338	Hematopoietic Tumors Primarily Presenting in Bone. Surgical Pathology Clinics, 2017, 10, 675-691.	1.7	9
339	High prevalence of autoimmune disease in the rare inflammatory bone disorder sternocostoclavicular hyperostosis: survey of a Dutch cohort. Orphanet Journal of Rare Diseases, 2017, 12, 20.	2.7	9
340	Nuclear factor-Î¹B activation in primary lymphoma of bone. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 349-354.	2.8	8
341	Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture. Clinical Sarcoma Research, 2015, 5, 16.	2.3	8
342	Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches. ChemBioChem, 2018, 19, 1758-1765.	2.6	8

#	Article	IF	Citations
343	New indicators and indexes for benchmarking universityâ€“industryâ€“government innovation in medical and life science clusters: results from the European FP7 Regions of Knowledge HealthTIES project. Health Research Policy and Systems, 2019, 17, 10.	2.8	8
344	Zebrafish as a Model for Human Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 221-236.	1.6	8
345	Antigen size influences the type of glomerular pathology in chronic serum sickness. Nephrology Dialysis Transplantation, 1993, 8, 703-710.	0.7	7
346	Skin Metastases of Osteogenic Sarcoma. Journal of Pediatric Hematology/Oncology, 1997, 19, 266.	0.6	7
347	MRI appearances of atypical cartilaginous tumour/grade I chondrosarcoma after treatment by curettage, phenolisation and allografting. Bone and Joint Journal, 2016, 98-B, 1674-1681.	4.4	7
348	NTRK fusions are extremely rare in bone tumours. Histopathology, 2021, 79, 880-885.	2.9	7
349	Re. Review Article entitled ?The neoplastic pathogenesis of solitary and multiple osteochondromas?. , 2000, 190, 516-517.		6
350	G2M arrest, blocked apoptosis, and low growth fraction may explain indolent behavior of head and neck paragangliomas. Human Pathology, 2003, 34, 690-698.	2.0	6
351	Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes. Journal of Internal Medicine, 2008, 264, 571-585.	6.0	6
352	Cancer biology and genomics: translating discoveries, transforming pathology. Journal of Pathology, 2011, 223, 99-101.	4.5	6
353	Maffucci syndrome: A genomeâ€wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases. Genes Chromosomes and Cancer, 2011, 50, 673-679.	2.8	6
354	Epidemiology of primary bone tumors and economical aspects of bone metastases. , 2015, , 5-10.		6
355	A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization. Cancer Genetics, 2015, 208, 537-544.	0.4	6
356	Glomerulopathy induced by a single monoclonal autoantibody against GP330. Nephrology Dialysis Transplantation, 1995, 10, 490-496.	0.7	5
357	Critical illness VR rehabilitation device (X-VR-D): Evaluation of the potential use for early clinical rehabilitation. Journal of Electromyography and Kinesiology, 2008, 18, 480-486.	1.7	5
358	Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 211-217.	2.8	5
359	Automation of Technology for Cancer Research. Advances in Experimental Medicine and Biology, 2016, 916, 315-332.	1.6	5
360	CXCR4 signaling is controlled by immobilization at the plasma membrane. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 607-616.	4.1	5

#	Article	IF	Citations
361	Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma. BMC Cancer, 2017, 17, 383.	2.6	5
362	Conjunctival Leiomyosarcoma, a Rare Neoplasm Always Originating at the Limbus? Report of a New Case and Review of 11 Published Cases. Ocular Oncology and Pathology, 2019, 5, 333-339.	1.0	5
363	Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. BMJ Open, 2019, 9, e022980.	1.9	5
364	The adapter protein Myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 265-275.	2.8	5
365	The histopathological differential diagnosis of mesenchymal tumours of the skin. Current Diagnostic Pathology, 2005, 11, 371-389.	0.4	4
366	Does parosteal liposarcoma differ from other atypical lipomatous tumors/well-differentiated liposarcomas? A molecular cytogenetic study using combined multicolor COBRA-FISH karyotyping and array-based comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2007, 176, 115-120.	1.0	4
367	Molecular genetics of chondroid tumours. Diagnostic Histopathology, 2014, 20, 165-171.	0.4	4
368	BCRP expression in schwannoma, plexiform neurofibroma and MPNST. Oncotarget, 2017, 8, 88751-88759.	1.8	4
369	Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. JMIR Research Protocols, 2019, 8, e14406.	1.0	4
370	Calcified meningioma of the skull base simulating chondrosarcoma. European Journal of Radiology, 1995, 21, 148-151.	2.6	3
371	An update of diagnostic strategies using molecular genetic and magnetic resonance imaging techniques for musculoskeletal tumors. Current Opinion in Rheumatology, 2000, 12, 77-83.	4.3	3
372	Women in healthcare in Imperial Russia: The contribution of the surgeon Nikolay I Pirogov. Journal of Medical Biography, 2021, 29, 9-18.	0.1	3
373	Pathology of soft tissue sarcomas with emphasis on molecular diagnostic techniques. European Journal of Cancer, Supplement, 2003, 1, 205-210.	2.2	2
374	CTâ€guided, COBRAâ€FISHâ€assisted diagnosis of wellâ€differentiated liposarcoma (inflammatory subtype) of the retroperitoneum. Histopathology, 2007, 51, 422-426.	2.9	2
375	The Journal of Pathology 2008 Jeremy Jass Prize for Research Excellence in Pathology. Journal of Pathology, 2009, 219, 393-395.	4.5	2
376	Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. Journal of Adolescent and Young Adult Oncology, 2011, 1, 118-123.	1.3	2
377	The clinical impact of molecular techniques on diagnostic pathology of soft tissue and bone tumours. Diagnostic Histopathology, 2012, 18, 81-85.	0.4	2
378	Mutations in the heparan sulfate backbone elongating enzymes EXT1 and EXT2 have no major effect on endothelial glycocalyx and the glomerular filtration barrier. Molecular Genetics and Genomics, 2022, 297, 397-405.	2.1	2

#	Article	IF	Citations
379	Soft tissue sarcomas: introduction to the Virchows Archiv review issue. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 107-109.	2.8	1
380	Co-existence of lung carcinoma metastasis and enchondroma in the femur of a patient with Ollier disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 479, 203-207.	2.8	1
381	Abstract 3780: Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in osteosarcoma cells. , 2015, , .		1
382	23 Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS) â€" eortc translational research project 01/01. Radiotherapy and Oncology, 2006, 78, S8-S9.	0.6	0
383	Soft tissue pathology. Current Diagnostic Pathology, 2006, 12, 83-88.	0.4	0
384	The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. International Journal of Experimental Pathology, 2009, 90, 190-191.	1.3	0
385	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
386	Non-Hodgkin lymphoma of bone of the femur and humerus: a case report and review of the literature. Oxford Medical Case Reports, 2021, 2021, omab024.	0.4	0